Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Safety and Efficacy of CryoCor™ Cryoablation for PAF

NCT00231296 · View on ClinicalTrials.gov ↗

Study Summary

A multi-center, randomized, controlled study of cryoablation vs medical management for the treatment of PAF

Conditions Studied

Interventions

  • DEVICE Cardiac CryoCor Cryoablation System
  • DRUG Medical management

Study Locations (20)

California

  • Regional Cardiology Associates — Sacramento
  • UCSD Medical Center — San Diego
  • UCSF Medical — San Francisco

Florida

  • University of Florida — Gainesville
  • University of South Florida — Tampa

Illinois

  • University of Chicago Hospitals — Chicago
  • Carle Heart Center — Urbana

Iowa

  • Genesis Health — Davenport
  • Iowa Heart Center — Des Moines

New York

  • St. Luke's-Roosevelt Hospital Center — New York
  • University of Rochester Medical Center — Rochester

Pennsylvania

  • Penn State Heart and Vascular Institute — Hershey
  • Drexel University — Philadelphia

Georgia

  • Emory University — Atlanta

Kentucky

  • Cardiology Associates of Kentucky — Lexington

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2004-11
Est. Completion 2009-03
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00231296

The ClinicalTrials.gov registry entry for NCT00231296 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions — of which Cardiac CryoCor Cryoablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00231296 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00231296 about?

NCT00231296 is a clinical study titled "Safety and Efficacy of CryoCor™ Cryoablation for PAF". A multi-center, randomized, controlled study of cryoablation vs medical management for the treatment of PAF

What is the current status of trial NCT00231296?

This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2004-11. Estimated completion is 2009-03.

What conditions does trial NCT00231296 study?

This clinical trial studies the following conditions: Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00231296?

The interventions under investigation include: Cardiac CryoCor Cryoablation System (DEVICE), Medical management (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00231296?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00231296 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial